8TH HEIDELBERG MYELOMA WORKSHOP - SCIENTIFIC PROGRAM FRIDAY, APRIL 16TH, 2021 SATURDAY, APRIL 17TH, 2021 - Universitätsklinikum ...

Page created by Jared Webster
 
CONTINUE READING
SCIENTIFIC PROGRAM

8TH HEIDELBERG
MYELOMA WORKSHOP
MULTIPLE MYELOMA – TODAY AND TOMORROW

Congress venue:
Online - Event

FRIDAY, APRIL 16TH, 2021
SATURDAY, APRIL 17 TH, 2021
DEAR COLLEAGUES,

Welcome to the 8th Heidelberg Myeloma Workshop.

Recent years have seen myeloma patients benefit from more
refined diagnostic criteria and a wider range of treatment
options. In particular, immunotherapies such as CAR T-cell
therapy have a high potential to improve myeloma therapy.
Other immunotherapeutic treatments are based on bispecific
 antibodies and so-called antibody-drug conjugates. Both
the earlier initiation of treatment and a greater appreciation
of the importance of targeting sustained deep remissions
offer new opportunities to further extend patient survival.

A precise delineation of the prognosis of different patient
groups can be achieved by the detection of genetic alte-
rations and characteristic clinical and molecular markers.
Trendsetting are the methods of imaging and molecular
medicine, which are combined within the framework of
systems medicine and continuously improve our understan-
ding of the disease.

The 8th Heidelberg Myeloma Workshop will start at 11.45
a.m. on Friday, the 16th of April, 2021. We hope that this pro-
gram will be of interest to you and look forward to welcoming
you at our virtual event.

Sincerely,

Prof. Dr. Hartmut Goldschmidt        Prof. Dr. Marc-Steffen Raab

Dr. rer. nat. Niels Weinhold
FRIDAY, APRIL 16TH, 2021
11.30 a.m. – 11.45 a.m.    Online Registration

11.45 a.m. – 12.00 p.m.
Introduction and Opening Remarks – 8th Heidelberg
Myeloma Workshop
Hartmut Goldschmidt, Heidelberg
Marc S. Raab, Heidelberg
Carsten Müller-Tidow, Heidelberg
Ingo Autenrieth, Heidelberg

SESSION I 		 12.00 p.m. – 1.45 p.m.
Diagnostics and Prognostic Factors
Chairmen: Niels Weinhold, Heidelberg

12.00 p.m. – 12.25 p.m.
Risk to progression in SMM
Maria Victoria Mateos, Salamanca

12.25 p.m. – 12.50 p.m.
How to define high-risk MM
Herve Avet-Loiseau, Toulouse

12.50 p.m. – 1.15 p.m.
Imaging based predictors of disease progression
Jens Hillengass, Buffalo

KEY NOTE LECTURE 		 1.15 p.m. – 1.45 p.m.
COVID-19 and other vaccinations
Heinz Ludwig, Wien

1.45 p.m. – 2.15 p.m. 		   Coffee Break - optional:
			                        Virtual Networking Room

SESSION II 		 2.15 p.m. – 3.55 p.m.
Advances in Immunotherapie
Chairmen: Michael Schmitt, Heidelberg

2.15 p.m. – 2.40 p.m.
Antibody-drug conjugates
Sagar Lonial, Atlanta

2.40 p.m. – 3.05 p.m.
Antibody-based T-Cell engagers
Marc-Steffen Raab, Heidelberg
3.05 p.m. – 3.30 p.m.
CAR-T cells targeting BCMA
Nikhil Munshi, Boston

3.30 p.m. – 3.55 p.m.
CARs beyond BCMA
Michael Hudecek, Würzburg

3.55 p.m. – 4.10 p.m.		    Virtual Short Coffee Break

SESSION III            4.10 p.m. – 6.20 p.m.
Current and future treatment standards
Chairmen: Florian Bassermann

4.10 p.m. – 4.35 p.m.
Should we treat SMM?
Ola Landgren, Miami

4.35 p.m. – 5.00 p.m.
High-risk MM
Katja Weisel, Hamburg

5.00 p.m.- 5.25 p.m.
Relapsed MM
Christoph Scheid, Köln

5.25 p.m.- 5.50 p.m.
First-line treatment in transplant-eligible patients
Phillippe Moreau, Nantes

KEY NOTE LECTURE 		 5.50 p.m. – 6.20 p.m.
Are we going to cure myeloma?
Brian Durie, Los Angeles

6.20 p.m.- 6.35 p.m.
Summary - Day one
Marc S. Raab / Hartmut Goldschmidt, Heidelberg
SATURDAY, APRIL 17TH, 2021
SESSION IV		            8.30 a.m. – 10.40 a.m.
MRD Driven Therapy – the new normal in Myeloma
Chairmen: Leo Rasche, Würzburg

8.30 a.m. – 8.55 a.m.
How to test MRD
Stefanie Huhn, Heidelberg

8.55 a.m. – 9.20 a.m.
Imaging and MRD
Elena Zamagni, Bologna

9.20 a.m. – 9.45 a.m.
Ready for guiding therapeutic decisions
Bruno Paiva, Pamplona

9.45 a.m. – 10.10 a.m.
Challenges and hurdles
Martin Kaiser, London

KEY NOTE LECTURE 		 10.10 a.m. – 10.40 a.m.
Screening for monoclonal gammopathy of undetermined
significance: A population-based randomized clinical
trial-the iStopMM study
Sigurdur Kristinsson, Reykjavik

10.40 a.m. – 10.55 a.m.   Virtual Coffee Break - optional:
			                       Virtual Networking Room

SESSION V 		 10.55 a.m. - 2.00 p.m.
Biology and Genomics of Multiple Myeloma
Chairmen: Christoph Driessen, St. Gallen

10.55 a.m. – 11.20 a.m.
Genomics of early MM
Niccolo Bolli, Milano

11.20 a.m. – 11.45 a.m.
Mechanisms in drug resistance
Martin Kortüm, Würzburg

11.45 a.m. – 12.10 p.m.
Future of Cereblon as a therapeutic target
Jan Krönke, Berlin

12.10 p.m. – 12.35 p.m.
Lessons from circulating tumor cells
Jens Lohr, Boston
12.35 p.m. – 1.00 p.m.
Spatial clonal evolution
Niels Weinhold, Heidelberg

1.00 p.m. – 1.30 p.m.		   Lunch Break - optional:
			                       Virtual Networking Room

KEY NOTE LECTURE 		 1.30 p.m. – 2.00 p.m.
Can biology guide treatment decisions in MM?
Gareth Morgan, New York

SESSION VI		            2.00 p.m. – 2.50 p.m.
German Study Groups – Quo vadis?
Chairmen: Roman Hajek, Ostrava

2.00 p.m. – 2.25 p.m.
DSMM
Hermann Einsele, Würzburg

2.25 p.m. – 2.50 p.m.
GMMG
Hartmut Goldschmidt, Heidelberg

2.50 p.m. – 3.05 p.m.
Summary of the 8th Heidelberg Myeloma Workshop
Marc S. Raab / Hartmut Goldschmidt
ORGANISATION AND CONGRESS VENUE

8TH HEIDELBERG MYELOMA WORKSHOP -
University Hospital Heidelberg
Department of Medicine V and
National Center for Tumor Diseases (NCT)
Multiple Myeloma Section
Im Neuenheimer Feld 410 | 69120 Heidelberg

CONTACT AND REGISTRATION

Nina Recke
Sektion Multiples Myelom
Medizinische Klinik V
Universitätsklinikum Heidelberg

Phone: 		             + 49 6221 56-8009
E-Mail: 		            nina.recke@med.uni-heidelberg.de
Register online at:   www.myelomaworkshop.de
We would like to thank all our sponsors for supporting the
8th Heidelberg Myeloma Workshop:

                    AbbVie Deutschland GmbH & Co.KG
                    65189 Wiesbaden | 12.500 €

                    Adaptive Biotechnologies
                    Seattle, Washington 98102| 12.500 €

 Amgen GmbH
 80992 München | 20.000 €

                    Bristol-Myers Squibb GmbH & Co. KGaA/Celgene
                    80636 München | 20.000 €

                    GlaxoSmithKline GmbH & Co. KG
                    81675 München | 12.500 €

                    Janssen-Cilag GmbH
                    41470 Neuss | 20.000 €

                    Oncopeptides AB
                    11153 Stockholm | 5.000 €

                    Pfizer Pharma GmbH
                    10785 Berlin | 5.000 €

                    Roche Pharma AG
                    79639 Grenzach-Wyhlen | 2.000 €

                    Sanofi-Aventis Deutschland GmbH
                    10785 Berlin | 20.000 €

  Sebia Labordiagnostische Systeme GmbH
  36041 Fulda | 2.000 €

                    Siemens Healthcare GmbH
                    65760 Eschborn | 1.000 €

                    Takeda Pharma Vertrieb GmbH & Co. KG
                    10117 Berlin | 6.500 €

                    The Binding Site GmbH
                    68723 Schwetzingen | 2.000 €

Sponsors will receive the opportunity to advertise their products
online before and/or after the event.
You can also read